Sun Pharma launches Volini Maxx, India’s Strongest Pain Relief Spray
Deepthi | Myequity news | Date : 29-08-2018 19:30:00 IST
Sun Pharma Consumer Healthcare, a division of Sun Pharmaceutical Industries Ltd, today announced the launch of Volini Maxx, India’s strongest pain relief spray. The company has signed Virat Kohli, Captain of Indian Cricket Team as the new brand ambassador of Volini. A 3600 marketing campaign featuring Virat Kohli goes live today.
Speaking about his association with Volini, Virat Kohli said, “I’m happy to partner with Volini and announce the launch of Volini Maxx - India’s strongest pain relief spray*. Athletes are required to push through pain on a regular basis, and Volini has been my trusted pain relief partner for decades. With its instant pain relief formulation, I am able to focus on my game and not the pain.”
Volini Maxx is a new variant of Sun Pharma’s popular brand, Volini - the No.1 pain relief spray in India. Its unique formulation of 2% diclofenac makes it 100% stronger than the existing 1% diclofenac sprays available in the Indian market. Volini Maxx is targeted for severe pains including musculoskeletal, joint and low back. Its 3600 technology ensures standardised drug delivery at all angles.
“Volini has been a trusted pain relief partner for over two decades. We are happy to introduce Volini Maxx spray which is stronger than any other topical pain relief spray available in India. It will provide effective relief to people suffering from back and joint pain & also in sports injuries,” said Kal Sundaram, CEO – India, Emerging Markets & Consumer Healthcare, Sun Pharma. “Known for pushing the limits of physical endurance, Virat echoes the brand vision of constantly improving performance and not letting pain come in the way of going that extra mile,” he added.
The overall topical analgesic market in India is valued at Rs. 3380 crores growing at 11% (AC Nielsen MAT June 18). Out of this, the spray category is around Rs. 356 crores growing at 18% (AC Nielsen MAT June 18).About Sun Pharmaceutical Industries Ltd:
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anticancers, steroids, peptides, sex hormones, and controlled substances.
The 2014 acquisition of Ranbaxy has made the company the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest specialty generic company globally. Over 72% of Sun Pharma sales are from markets outside India, primarily in the US. The US is the single largest market, accounting for about 50% turnover; in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 26 locations, including plants in the US, Canada, Brazil, Mexico and Israel. In the US, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).